NASDAQ:PGEN Precigen Q3 2025 Earnings Report $4.07 +0.13 (+3.17%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Precigen EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/APrecigen Revenue ResultsActual RevenueN/AExpected Revenue$0.67 millionBeat/MissN/AYoY Revenue GrowthN/APrecigen Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Precigen Earnings HeadlinesA Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory PapillomatosisOctober 17, 2025 | finance.yahoo.comPatient Opportunity Equity Strategy Q3 2025 Portfolio RecapOctober 16, 2025 | seekingalpha.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 21 at 2:00 AM | Banyan Hill Publishing (Ad)Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for ...October 13, 2025 | finance.yahoo.comPrecigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory PapillomatosisOctober 13, 2025 | prnewswire.comPrecigen, Inc. (NASDAQ:PGEN) Receives $8.25 Average Target Price from AnalystsOctober 13, 2025 | americanbankingnews.comSee More Precigen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email. Email Address About PrecigenPrecigen (NASDAQ:PGEN) (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects. The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products. By using a modular receptor system, OmniCAR T cells can be retargeted against multiple tumor antigens through the administration of different adaptor molecules. In addition, Precigen’s ActoBiotics platform engineers live bacterial strains to deliver therapeutic payloads at disease sites, offering a novel route to treat gastrointestinal and other localized disorders. Precigen’s clinical pipeline includes several early- to mid-stage programs. In oncology, the company is evaluating OmniCAR candidates targeting hematologic malignancies and solid tumors. The ActoBiotics pipeline features programs for inflammatory bowel disease and metabolic disorders. Precigen also maintains research collaborations and licensing partnerships aimed at expanding the utility of its gene control and vector technologies across diverse therapeutic areas. Originally founded in 1998 as Intrexon Corporation, the company rebranded as Precigen in 2020 to reflect its strategic focus on precision genetic medicine. Headquartered in Germantown, Maryland, Precigen operates research and manufacturing sites in the United States and Europe. Under the leadership of President and CEO Helen Sabzevari, PhD, the company continues to build its pipeline and advance next-generation therapies toward regulatory milestones and commercialization.View Precigen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings CME Group (10/22/2025)Lam Research (10/22/2025)O'Reilly Automotive (10/22/2025)Tesla (10/22/2025)Amphenol (10/22/2025)Barclays (10/22/2025)Boston Scientific (10/22/2025)GE Vernova (10/22/2025)Hilton Worldwide (10/22/2025)International Business Machines (10/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
